Want to see JP:8086 full AI Analyst Report?
Top Page
Nipro
(8086)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥1,306.00
▼(-13.08% Downside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by financial risk factors: consistently negative free cash flow and a highly leveraged balance sheet, despite steady revenue growth and some operating margin improvement. Technical signals are neutral-to-soft with limited momentum, while valuation is reasonable (mid P/E with a modest dividend) but not compelling enough to outweigh cash flow and leverage concerns.
Positive Factors
Steady Revenue Expansion
Revenue growth across several years indicates expanding demand for Nipro’s healthcare and pharmaceutical-related products. This provides a durable base for scale benefits, supports continued investment, and may strengthen customer relationships across medical and drug-manufacturing markets.
Negative Factors
High Financial Leverage
Debt remains elevated relative to equity, leaving Nipro with less financial flexibility if margins weaken or cash generation stays pressured. High leverage can also direct operating cash toward debt servicing and restrict the company’s ability to fund growth or absorb setbacks.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady Revenue Expansion
Revenue growth across several years indicates expanding demand for Nipro’s healthcare and pharmaceutical-related products. This provides a durable base for scale benefits, supports continued investment, and may strengthen customer relationships across medical and drug-manufacturing markets.
Read all positive factors
Nipro (8086) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥215.12B
Dividend Yield2.35%
Average Volume (3M)750.63K
Price to Earnings (P/E)15.3
Beta (1Y)0.40
Revenue Growth2.68%
EPS Growth144.20%
CountryJP
Employees38,593
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)86.21
Shares Outstanding171,459,470
10 Day Avg. Volume938,020
30 Day Avg. Volume750,626
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.92
Price to Sales (P/S)0.38
P/FCF Ratio-32.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)92.94
Revenue Forecast (FY)¥703.83B
Nipro Business Overview & Revenue Model
Company Description
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, producti...
How the Company Makes Money
Nipro makes money primarily by selling healthcare and pharmaceutical-related products and services to hospitals, clinics, dialysis centers, and pharmaceutical manufacturers. Key revenue streams include: (1) Medical devices and consumables: recurri...
Nipro Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
44
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 668.86B | 660.54B | 644.59B | 586.78B | 545.20B | 494.79B |
| Gross Profit | 212.10B | 208.28B | 193.66B | 173.98B | 165.90B | 151.84B |
| EBITDA | 101.17B | 102.99B | 92.58B | 84.62B | 70.02B | 73.60B |
| Net Income | 14.07B | 13.50B | 5.11B | 11.11B | 4.58B | 13.46B |
Balance Sheet | ||||||
| Total Assets | 1.22T | 1.21T | 1.18T | 1.12T | 1.04T | 938.35B |
| Cash, Cash Equivalents and Short-Term Investments | 104.86B | 97.83B | 106.67B | 99.67B | 89.68B | 95.34B |
| Total Debt | 661.52B | 638.31B | 636.87B | 635.69B | 605.93B | 564.85B |
| Total Liabilities | 876.85B | 878.51B | 864.77B | 849.18B | 793.62B | 738.49B |
| Stockholders Equity | 283.21B | 274.12B | 252.45B | 232.66B | 206.32B | 185.24B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -7.67B | -8.15B | -21.33B | -74.70B | -11.74B |
| Operating Cash Flow | 0.00 | 54.66B | 68.46B | 72.94B | 10.39B | 68.21B |
| Investing Cash Flow | 0.00 | -55.33B | -71.88B | -87.08B | -71.74B | -78.43B |
| Financing Cash Flow | 0.00 | -8.14B | 5.38B | 22.14B | 43.08B | 10.30B |
Nipro Technical Analysis
Negative
1502.50
Price Trends
1494.48
Negative
1560.93
Negative
1528.29
Negative
Market Momentum
-48.74
Positive
29.58
Positive
24.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8086, the sentiment is Negative. The current price of 1502.5 is above the 20-day moving average (MA) of 1391.34, above the 50-day MA of 1494.48, and below the 200-day MA of 1528.29, indicating a bearish trend. The MACD of -48.74 indicates Positive momentum. The RSI at 29.58 is Positive, neither overbought nor oversold. The STOCH value of 24.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:8086.
Nipro Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥3.37T | 20.48 | 10.60% | 1.54% | 14.05% | 31.94% | |
78 Outperform | ¥892.29B | 27.89 | 19.88% | 1.43% | 21.16% | 156.97% | |
71 Outperform | ¥1.12T | 29.09 | 8.02% | 2.15% | 4.48% | -15.75% | |
70 Outperform | ¥2.20T | 28.11 | 10.21% | 2.94% | 7.80% | -27.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥215.12B | 15.30 | 5.35% | 2.36% | 2.68% | 144.20% |
* Healthcare Sector Average
JP:8086
Nipro
1,319.00
-142.24
-9.73%
JP:4543
Terumo
2,284.00
-173.47
-7.06%
JP:7747
Asahi Intecc Co
3,363.00
1,033.56
44.37%
JP:7733
Olympus
2,000.00
212.25
11.87%
JP:6869
Sysmex
1,855.00
17.07
0.93%
Nipro Corporate Events
Nipro Nearly Completes Conversion of 2026 Euro-Yen Convertible Bonds
Sep 15, 2026
Nipro Corporation has announced the near-complete conversion of its Euro-Yen Denominated Convertible Bonds due 2026, originally issued in September 2021 with a total principal of 30,000 million yen. Bondholders exercised conversion rights on 29,93...
Nipro lifts profits in first quarter, keeps guidance and plans higher dividend
Aug 10, 2026
Nipro reported consolidated results for the quarter ended June 30, 2026, with net sales rising 5.2% year on year to ¥167.5 billion and operating profit up 6.9% to ¥7.7 billion. Ordinary profit surged 87.8% to ¥6.6 billion and profit...
Nipro to Book JPY 3.9 Billion Extraordinary Gain From Atonarp Share Sale
Jul 29, 2026
Nipro Corporation has approved the sale of its shareholding in Atonarp Inc., an unlisted investee company, following Atonarp’s agreement to be acquired by V AT Holding AG. The transaction was initiated by a request from V AT Holding AG, conv...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.